|Mr. Sandesh C. Seth||Chairman & CEO||825k||N/A||1964|
|Mr. Steven O'Loughlin BS||Principal Financial & Accounting Officer||360k||N/A||1986|
|Dr. Dale L. Ludwig Ph.D.||Chief Scientific Officer||323.77k||N/A||1962|
|Dr. Mark S. Berger||Chief Medical Officer||475k||N/A||1955|
|Mr. Anil Kapur||Chief Commercial Officer||294.4k||N/A||1969|
Actinium Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, Iomab-B that is in a pivotal Phase III clinical trial as an induction and conditioning agent in patients over the age of 55 with relapsed or refractory acute myeloid leukemia prior to receiving a bone marrow transplant, also known as a hematopoietic stem cell transplant. The company is also developing Actimab-A, its lead alpha-particle drug candidate that is in a Phase II trial for patients newly diagnosed with AML age 60 and over; and Actimab-M, a drug candidate, which is being studied in patients with relapsed or refractory multiple myeloma in a Phase 1 clinical trial. Its Antibody Warhead Enabling technology platform is currently being utilized in a research collaboration with Astellas Pharma, Inc. Actinium Pharmaceutical, Inc. was founded in 2000 and is based in New York, New York.
Actinium Pharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.